BiotechTV - News

CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16.

He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech.

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run early stage clinical trials in the U.S. and for it to be less costly for small biotech companies to...

CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner.

CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and vaccines.

CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well.

CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year.

Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises.

CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.

Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome.

Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.

Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.

Jim Olaghere describes signing up for a gene editing treatment clinical trial for sickle cell disease and how it has enabled him to climb mountains and Bob Coughlin recounts the moment when a therapy became available for his son's cystic fibrosis.

Alexis Borisy recounts the story of Revolution Medicines, which delivered the pancreatic cancer breakthrough this year, and talks about the health of the founder led side of the biotech sector. Mathai Mammen recently took Parabilis public in the largest IPO in biotech history, and describes the science that made it possible.

He describes how science 'keeps you young' because it always based on what you don't know. He urges scientists to stay humble when talking about science to the public because things can change, and he shares stories from his career and offers advice on how to keep the United States globally competitive.

Interviewed by HSBC Innovation Banking's Katherine Andersen, Najat Khan discusses AI, her priorities upon taking the role of CEO at Recursion earlier this year, encouraging employees to speak more than just one language of expertise, and women in leadership.

Moderated by BiotechTV's Chloe Kirk, Gabriel Astorga (@GoodOlGab), Maynard Okereke (@HipHopScienceShow), and Alex Dainis (@AlexDainis) describe how the got started posting about science on social media and how they grew their audiences to what they are today. Plus, advice for companies and scientists about how to resonate the best.

The combined following of the group reaches approximately 3 million people on Instagram and TikTok.

He describes the format and goals of the event.

Moderated by MassBio CEO Kendalle Burlin O'Connel, Kymera Therapeutics CEO Nello Mainolfi, CRISPR Therapeutics CEO Samarth Kulkarni, and Ginkgo Bioworks CEO Jason Kelly discuss their companies' innovations (protein degradation, CRISPR gene editing, and autonomous labs), how the U.S. can increase its competitiveness, and the 'Why' that motivates them each day. 

Dr. Zerhouni, the Founder and Chair of ModeX Therapeutics and Former NIH Director, talks about investments in science that started with Vannevar Bush, current day NIH funding, adding a political element to the grant making process, science communication, and more.

The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.

Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemotherapy, and he discusses the medicine's side effect profile. Plus, next steps for this treatment in pancreatic cancer and beyond.

Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.